Login / Signup

Facile protein conjugation of platinum for light-activated cytotoxic payload release.

Cinzia ImbertiFrederik LermyteEmily P FriarPeter B O'ConnorPeter J Sadler
Published in: Chemical communications (Cambridge, England) (2021)
The novel Pt(iv) complex trans,trans-[Pt(N3)2(Py)2(OH)(OCO-(PEG)2-NHCSNH-Ph-NCS)] (Pt4) conjugates to the side chain of lysine amino acids in proteins under mild conditions. Reaction with myoglobin generated a bioconjugate that was stable in the dark, but released a Pt(iv) prodrug upon visible light irradiation. A similar procedure was used to conjugate Pt4 to the antibody trastuzumab, resulting in the first photoactivatable Pt(iv)-antibody conjugate, demonstrating potential for highly selective cancer phototherapy.
Keyphrases
  • visible light
  • amino acid
  • cancer therapy
  • drug delivery
  • radiation therapy
  • papillary thyroid
  • squamous cell carcinoma
  • young adults
  • quantum dots
  • binding protein
  • reduced graphene oxide
  • squamous cell